Clarity PharmaceuticalsASX:CU6 -11.03%39 Current Ratio is 11.43 as of Dec. 2025, which is 9% below its 10-year median of 12.51. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Clarity Pharmaceuticals ranks better than 80.89% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Clarity Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 11.43.
Clarity Pharmaceuticals has a current ratio of 11.43. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Clarity Pharmaceuticals's Current Ratio or its related term are showing as below:
ASX:CU6'
s Current Ratio Range Over the Past 10 Years
Min: 9.69 Med: 12.51 Max: 58.83
Current: 11.43
During the past 4 years, Clarity Pharmaceuticals's highest Current Ratio was 58.83. The lowest was 9.69. And the median was 12.51.
ASX:CU6's Current Ratio is ranked better than 80.89% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs ASX:CU6: 11.43
Clarity Pharmaceuticals (ASX:CU6) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Clarity Pharmaceuticals Current Ratio Related Terms
Clarity Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CU6 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Clarity Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarity Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Clarity Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarity Pharmaceuticals (ASX:CU6) has a Current Ratio of 11.43 as of Dec. 2025. This is near median its historical median of 12.51. Over the past decade, Clarity Pharmaceuticals' Current Ratio has ranged from 9.69 to 58.83. According to the industry distribution chart, Clarity Pharmaceuticals ranks #270 out of 1413 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Clarity Pharmaceuticals' Current Ratio too high?
Clarity Pharmaceuticals' current Current Ratio of 11.43 is near median its 10-year median of 12.51. Over the past 10 years, this metric has ranged from a low of 9.69 to a high of 58.83. The Biotechnology industry median Current Ratio is 3.89. Clarity Pharmaceuticals' value of 11.43 is 193.8% above this industry median. Based on the distribution chart, Clarity Pharmaceuticals ranks #270 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #270 out of 1413 companies for Current Ratio. This places Clarity Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Clarity Pharmaceuticals' value of 11.43 is 193.8% above this benchmark. Historically, Clarity Pharmaceuticals' own Current Ratio has ranged from 9.69 to 58.83 over the past decade. While the company's 10-year median is 12.51 vs. the industry median of 3.89, Clarity Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clarity Pharmaceuticals's current Current Ratio of 11.43 is 193.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current Current Ratio is 11.43, which is near median its own 10-year median of 12.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Current Ratio of 11.43. The current Current Ratio is 11.43, which is near median its 10-year median of 12.51 and 193.8% above the Biotechnology industry median of 3.89. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Current Ratio is 11.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score
Get the complete analysis for ASX:CU6
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CU6 has been successfully added to your 
